EQT has agreed to a deal to acquire the biosurgery business of Corza Medical from private equity firm GTCR. The acquisition includes the TachoSil product portfolio, a key asset that EQT believes has a strong clinical value proposition and physician preference.

GTCR, which formed Corza Medical in 2019, previously acquired TachoSil in 2021 and integrated it with Surgical Specialties. The firm then executed several operational improvements and add-on acquisitions to expand the business's reach, particularly in minimally invasive and robotic surgery.

This transaction allows GTCR to redeploy capital into its remaining Corza Medical units, focusing on wound closure, ophthalmology, and biomedical textiles. For EQT, the deal provides a standalone biosurgery business that it plans to scale internationally. The acquisition is expected to close in the fourth quarter of 2026.

This divestiture marks a strategic shift for GTCR, allowing them to capitalize on the value created in the biosurgery segment while continuing to invest in other areas of Corza Medical. EQT's move signals confidence in the medical device sector and its potential for international expansion.